Comparison of C - Reactive Protein and Lipid Profile in Obese Poly Cystic Ovary Syndrome Women and Normal Women of the Reproductive Age Group – A Prospective Case-Controlled Trial
Life Sciences-CRP and Lipid in Obese PCO
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP25.L1-5Keywords:
Poly Cystic Ovary Syndrome, Obesity C-Reactive Protein, Body Mass Index, Lipid Profile and DyslipidemiaAbstract
Serum (C Reactive Protein) CRP is a good predictor of vascular events and has been linked to polycystic ovarian syndrome (PCOS). The increased CRP may be an early marker of upcoming atherosclerotic diseases like coronary artery disease and stroke. To identify the disease of PCOS and its interrelation with increased CRP may work as a clue for its disease progression. The purpose of this study is to evaluate the high-sensitivity C- reactive protein, which is a characteristic of individuals with PCOS of reproductive age. The sample size for this prospective randomized study was 200 people, divided into two equal groups (with or without PCOS). This study included 100 obese women with the polycystic ovarian syndrome and 100 matched controls. These women's blood samples were tested for serum lipid profile and hsCRP.. The demographic variables were similar between the groups. Our findings revealed that patients with PCOS had high LDL and triglyceride levels. HDL levels were extremely low. This indicates a poor lipid profile in PCOS patients. (The p-value is 0.001). The hs CRP was 9.3 mg compared to 2.9 mg in the control group. According to our findings, hs CRP may provide information about the presence of the disease. As a result, more research is needed to explain the potential role of C-reactive protein in the disease incidence and progression of polycystic ovarian syndrome. Even though there are a lot of studies linking these two, we have done for Hs CRP and PCOS. The sample size is on the higher side in our study.
References
Hart R, Hickey M, Franks S. R, HickeyM,Franks S 2004 Definitions,prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):671-83. doi: 10.1016/j.bpobgyn.2004.05.001, PMID 15380140.
Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763-71. doi: 10.1161/hh2101.099270, PMID 11679405.
Kim JW, Han JE, Kim YS, Won HJ, Yoon TK, Lee WS. High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(4):259-63. doi: 10.3109/09513590.2011.613967, PMID 21970575.
Al-Tu’ma FJ, Abd-Yaser ZA, Al-Naffi KO. Association between hs-CRP levels and the severity of coronary atherosclerosis. J Contemp Med Sci. Spring 2016;2(6):42-4.
Ridker PM, Cook NR. Biomarkers for prediction of cardiovascular events. N Engl J Med. 2007;356(14):1472-3; author reply 1474. doi: 10.1056/NEJMc070079, PMID 17415901.
Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol. 2004;150(4):525-32. doi: 10.1530/eje.0.1500525, PMID 15080783.
Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123-7. doi: 10.1016/s0015-0282(03)00571-5, PMID 12849813.
Al-Tu’ma FJ, Al-Faris NN, Al-Safi WG. Total antioxidant capacity and homocystine levels in obese polycystic ovary syndrome patients (accepted in international journal of pharmacy and pharmaceutical research, 2017).
Cupisti S, Kajaia N, Dittrich R, Duezenli H, W Beckmann MW, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol. 2008;158(5):711-9. doi: 10.1530/EJE-07-0515, PMID 18426831.
Gayatri K, Kumar JS, Kumar BB. Metformin and N-acetylcysteine in polycystic ovarian syndrome—A comparative study. Indian J Clin Med. 2010;1:7. doi: 10.1177/117739361000100002.
Hamilton CJ, Jaroudi KA, Sieck UV. High prevalence of obesity in a Saudi infertility population. Ann Saudi Med. 1995;15(4):344-6. doi: 10.5144/0256-4947.1995.344, PMID 17590603.
Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002;77(6):1128-35. doi: 10.1016/s0015-0282(02)03133-3, PMID 12057717.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929-35. doi: 10.1210/jc.2004-1045, PMID 15623819.
Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154(1):141-5. doi: 10.1530/eje.1.02058, PMID 16382003
Published
How to Cite
Issue
Section
Copyright (c) 2022 Dr. Revathi R, Dr. Balaji Rajagopalan, Dr. Swetha, Dr. V. Kuzhandai Velu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
